Globus Medical Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Globus Medical de 31.6% y 14% por año respectivamente. Se prevé que el BPA crezca en un 31.2% al año. Se espera que la rentabilidad financiera sea de 11.6% en 3 años.

Información clave

40.9%

Tasa de crecimiento de los beneficios

39.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.6%
Tasa de crecimiento de los ingresos	11.2%
Rentabilidad financiera futura	10.2%
Cobertura de analistas	Good
Última actualización	20 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued

Apr 08

Globus Medical Non-GAAP EPS of $0.50 misses by $0.02, revenue of $254.15M in-line

Nov 08

A Look At The Fair Value Of Globus Medical, Inc. (NYSE:GMED)

Oct 15

Globus Medical: Compelling Long-Term Value On Offer, Buy Thesis Intact

Sep 02

Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

Sep 02

Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?

Aug 11

Globus Medical: Low Rates Sensitivity, Seeking 26% Return Objective

Jun 05

Globus Medical (NYSE:GMED) May Have Issues Allocating Its Capital

May 24

Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?

May 06

An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 22% Undervalued

Mar 14

Globus Medical Continues To Flex Its Innovation Muscles To Drive Share Growth

Mar 01

Globus Medical's (NYSE:GMED) Performance Is Even Better Than Its Earnings Suggest

Feb 24

Returns On Capital At Globus Medical (NYSE:GMED) Paint A Concerning Picture

Feb 08

Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?

Jan 21

Previsiones de crecimiento de beneficios e ingresos

NYSE:GMED - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	2,853	456	N/A	N/A	10
12/31/2025	2,654	382	750	N/A	14
12/31/2024	2,475	227	908	N/A	14
3/31/2024	1,898	67	152	243	N/A
12/31/2023	1,568	123	165	243	N/A
9/30/2023	1,226	158	129	203	N/A
6/30/2023	1,097	204	121	185	N/A
3/31/2023	1,069	201	117	187	N/A
12/31/2022	1,023	190	104	178	N/A
9/30/2022	998	155	118	191	N/A
6/30/2022	974	155	157	235	N/A
3/31/2022	961	142	194	257	N/A
12/31/2021	958	149	219	276	N/A
9/30/2021	942	187	226	280	N/A
6/30/2021	928	184	203	256	N/A
3/31/2021	826	122	165	220	N/A
12/31/2020	789	102	135	199	N/A
9/30/2020	767	95	108	173	N/A
6/30/2020	747	89	115	176	N/A
3/31/2020	793	148	110	175	N/A
12/31/2019	785	155	101	172	N/A
9/30/2019	770	146	90	162	N/A
6/30/2019	743	143	82	158	N/A
3/31/2019	722	150	93	169	N/A
12/31/2018	713	156	122	182	N/A
9/30/2018	693	144	126	182	N/A
6/30/2018	676	134	112	165	N/A
3/31/2018	655	118	106	158	N/A
12/31/2017	636	107	N/A	159	N/A
9/30/2017	612	107	N/A	166	N/A
6/30/2017	595	108	N/A	174	N/A
3/31/2017	581	105	N/A	171	N/A
12/31/2016	564	104	N/A	148	N/A
9/30/2016	553	118	N/A	166	N/A
6/30/2016	554	118	N/A	153	N/A
3/31/2016	548	116	N/A	143	N/A
12/31/2015	537	113	N/A	124	N/A
9/30/2015	518	103	N/A	80	N/A
6/30/2015	499	99	N/A	85	N/A
3/31/2015	481	96	N/A	85	N/A
12/31/2014	467	92	N/A	79	N/A
9/30/2014	454	86	N/A	110	N/A
6/30/2014	443	83	N/A	108	N/A
3/31/2014	436	70	N/A	104	N/A
12/31/2013	427	69	N/A	93	N/A
9/30/2013	420	68	N/A	86	N/A
6/30/2013	407	65	N/A	69	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (31.6% al año) de GMED es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (31.6% al año) de GMED crezcan más rápidamente que el mercado US (14.7% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de GMED crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (14% al año) de GMED crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 14% al año) de GMED crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de GMED sea baja dentro de 3 años (11.6%).

Globus Medical Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 7.8% to US$70.42

Globus Medical, Inc. Updates Earnings Guidance for the Full Year 2024

Consensus EPS estimates fall by 21%

Globus Medical, Inc. Reaffirms Revenue Guidance for the Full Year 2024

Consensus EPS estimates fall by 32%

Globus Medical, Inc. Revises Earnings Guidance for the Year 2023

Recent updates

Price target increased by 7.8% to US$70.42

Independent Director recently sold US$698k worth of stock

Globus Medical, Inc. Updates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Globus Medical, Inc., Annual General Meeting, Jun 05, 2024

Globus Medical, Inc. to Report Q1, 2024 Results on May 07, 2024

An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued

Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly

Director notifies of intention to sell stock

Senior VP notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock

Full year 2023 earnings: EPS misses analyst expectations

Globus Medical, Inc. Reaffirms Revenue Guidance for the Full Year 2024

Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?

Globus Medical Promotes Keith Pfeil to Chief Operating Officer

Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings

Globus Medical, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Globus Medical: Merger Overhang Lingering

Does Globus Medical (NYSE:GMED) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 32%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Globus Medical, Inc. Revises Earnings Guidance for the Year 2023

Should You Investigate Globus Medical, Inc. (NYSE:GMED) At US$46.27?

Globus Medical, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Globus Medical: Almost Having My Back

New minor risk - Shareholder dilution

Globus Medical, Inc. (NYSE:GMED) completed the acquisition of NuVasive, Inc. (NasdaqGS:NUVA) from BlackRock, Inc. (NYSE:BLK), The Vanguard Group, Inc., Thrivent Financial for Lutherans and others.

Globus Medical: Slightly Too Pricey Right Now

Globus Medical, Inc. Updates Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Globus Medical, Inc. Announces Launch of the Marvel(Tm) Growing Rod System

Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy

Globus Medical, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?

Globus Medical, Inc.(NYSE:GMED) dropped from Russell 1000 Growth-Defensive Index

Here's Why We Think Globus Medical (NYSE:GMED) Is Well Worth Watching

Independent Director exercised options and sold US$1.4m worth of stock

Globus Medical, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

What Is Globus Medical, Inc.'s (NYSE:GMED) Share Price Doing?

Do Globus Medical's (NYSE:GMED) Earnings Warrant Your Attention?

Full year 2022 earnings: EPS misses analyst expectations

Globus Medical Q4 2022 Earnings Preview

Independent Director exercised options to buy US$334k worth of stock.

Price target decreased by 7.3% to US$72.58

Globus Medical, Inc. (NYSE:GMED) entered into a definitive agreement to acquire NuVasive, Inc. (NasdaqGS:NUVA) for $3.1 billion.

Investor sentiment deteriorates as stock falls 20%

Senior VP & CFO exercised options and sold US$760k worth of stock

Globus Medical, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Independent Director exercised options to buy US$566k worth of stock.

Globus Medical: An Impressive Long-Term Revenue Growth Play

Insufficient new directors

Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?

Senior VP exercised options and sold US$468k worth of stock

Globus Medical (NYSE:GMED) Will Want To Turn Around Its Return Trends

Third quarter 2022 earnings: EPS misses analyst expectations

Globus Medical, Inc. Reaffirms Net Sales Guidance for the Year 2022

Globus Medical Non-GAAP EPS of $0.50 misses by $0.02, revenue of $254.15M in-line

Globus Medical, Inc. to Report Q3, 2022 Results on Nov 08, 2022

A Look At The Fair Value Of Globus Medical, Inc. (NYSE:GMED)

Globus Medical: Compelling Long-Term Value On Offer, Buy Thesis Intact

Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around

Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?

Globus Medical, Inc. Reaffirms Sales Guidance for the Full Year 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Globus Medical, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Globus Medical: Low Rates Sensitivity, Seeking 26% Return Objective